Total Payments
$5,911
2024 Payments
$2,285
Companies
32
Transactions
380
Medicare Patients
4,978
Medicare Billing
$2.6M
Payment Breakdown by Category
Food & Beverage$5,911 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,911 | 380 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,582 | 92 | $0 (2024) |
| Amgen Inc. | $1,166 | 93 | $0 (2024) |
| Janssen Biotech, Inc. | $876.31 | 56 | $0 (2024) |
| UCB, Inc. | $506.83 | 42 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $499.88 | 29 | $0 (2024) |
| Novo Nordisk Inc | $148.86 | 7 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $111.42 | 6 | $0 (2024) |
| Radius Health, Inc. | $96.81 | 6 | $0 (2024) |
| Averitas Pharma Inc. | $77.99 | 3 | $0 (2023) |
| CALLIDITAS THERAPEUTICS US INC. | $70.44 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,285 | 142 | ABBVIE INC. ($590.07) |
| 2023 | $2,887 | 188 | AbbVie Inc. ($798.26) |
| 2022 | $738.98 | 50 | Amgen Inc. ($193.88) |
All Payment Transactions
380 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.04 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $1.82 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.90 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $5.43 | General |
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Inflammation | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $2.67 | General |
| Category: Dermatology | ||||||
| 11/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $12.94 | General |
| 11/06/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: Inflammation | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $0.95 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: Bone Health | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 3,579 | 205,551 | $7.6M | $2.3M |
| 2022 | 27 | 1,399 | 22,393 | $921,713 | $301,206 |
Total Patients
4,978
Total Services
227,944
Medicare Billing
$2.6M
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 101 | 28,850 | $1.9M | $970,843 | 51.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 92 | 40,437 | $2.2M | $425,818 | 19.3% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 48 | 72,000 | $1.4M | $281,975 | 19.6% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 31 | 52,723 | $632,676 | $248,636 | 39.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 16 | 3,114 | $467,100 | $82,087 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 370 | 868 | $175,336 | $73,584 | 42.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 157 | 401 | $140,350 | $36,405 | 25.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 22 | 1,440 | $47,520 | $27,125 | 57.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 50 | 432 | $63,504 | $22,093 | 34.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 103 | 150 | $40,500 | $18,316 | 45.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 132 | 403 | $67,704 | $17,774 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 135 | 135 | $41,850 | $15,442 | 36.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 78 | 146 | $37,625 | $8,084 | 21.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 345 | 643 | $10,288 | $5,315 | 51.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 34 | 34 | $13,260 | $5,313 | 40.1% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 69 | 136 | $34,030 | $5,074 | 14.9% |
| 86480 | Tuberculosis test, gamma interferon | Office | 2023 | 72 | 75 | $17,025 | $4,556 | 26.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 236 | 433 | $71,445 | $4,444 | 6.2% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 49 | 105 | $18,304 | $3,728 | 20.4% |
| 80074 | Acute hepatitis panel | Office | 2023 | 79 | 80 | $28,600 | $3,692 | 12.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 56 | $7,840 | $3,450 | 44.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 202 | 393 | $17,292 | $2,962 | 17.1% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 258 | 507 | $26,871 | $2,550 | 9.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 28 | 89 | $9,879 | $1,813 | 18.4% |
| 85652 | Red blood cell sedimentation rate, to detect inflammation, automated | Office | 2023 | 254 | 500 | $14,000 | $1,312 | 9.4% |
About Dr. David Chetrit, MD
Dr. David Chetrit, MD is a Rheumatology healthcare provider based in Myrtle Beach, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2017. The National Provider Identifier (NPI) number assigned to this provider is 1285155010.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Chetrit, MD has received a total of $5,911 in payments from pharmaceutical and medical device companies, with $2,285 received in 2024. These payments were reported across 380 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($5,911).
As a Medicare-enrolled provider, Chetrit has provided services to 4,978 Medicare beneficiaries, totaling 227,944 services with total Medicare billing of $2.6M. Data is available for 2 years (2022–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Myrtle Beach, SC
- Active Since 07/01/2017
- Last Updated 07/28/2023
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1285155010
Products in Payments
- RINVOQ (Biological) $1,146
- Enbrel (Biological) $804.49
- TREMFYA (Drug) $662.56
- Cimzia (Drug) $484.75
- COSENTYX (Drug) $427.70
- SKYRIZI (Biological) $241.00
- Otezla (Drug) $134.12
- KRYSTEXXA (Biological) $128.22
- REMICADE (Biological) $116.81
- SIMPONI ARIA (Biological) $114.10
- Wegovy (Drug) $100.94
- Tymlos (Drug) $85.08
- OFEV (Drug) $82.31
- QUTENZA (Drug) $77.99
- TARPEYO (Drug) $70.44
- LUPKYNIS (Drug) $63.41
- XELJANZ (Drug) $59.94
- ACTHAR (Biological) $58.50
- BENLYSTA (Biological) $55.94
- Crysvita (Drug) $52.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Myrtle Beach
Douglas Conaway, M.d, M.D
Rheumatology — Payments: $794,524
Rheumatology $794,524
Dr. David Lazar, M.d, M.D
Rheumatology — Payments: $31,010
Rheumatology $31,010
Wendy Lee, Md, MD
Rheumatology — Payments: $22,900
Rheumatology $22,900
Rabih Nayfe, M.d, M.D
Rheumatology — Payments: $18,167
Rheumatology $18,167
Jon Twining, Md, MD
Rheumatology — Payments: $17,936
Rheumatology $17,936